TY - JOUR
T1 - Electronic Cigarette Use in US Adults at Risk for or with COPD
T2 - Analysis from Two Observational Cohorts
AU - For Copdgene And Spiromics Investigators
AU - Bowler, Russell P.
AU - Hansel, Nadia N.
AU - Jacobson, Sean
AU - Graham Barr, R.
AU - Make, Barry J.
AU - Han, Mei Lan K.
AU - O’Neal, Wanda K.
AU - Oelsner, Elizabeth C.
AU - Casaburi, Richard
AU - Barjaktarevic, Igor
AU - Cooper, Chris
AU - Foreman, Marilyn
AU - Wise, Robert A.
AU - DeMeo, Dawn L.
AU - Silverman, Edwin K.
AU - Bailey, William
AU - Harrington, Kathleen F.
AU - Woodruff, Prescott G.
AU - Drummond, M. Bradley
N1 - Funding Information:
Funders: SPIROMICS was supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), which were supplemented by contributions made through the Foundation for the NIH from AstraZeneca; Bellerophon Therapeutics; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici SpA; Forest Research Institute, Inc.; GSK; Grifols Therapeutics, Inc.; Ikaria, Inc.; Nycomed GmbH; Takeda Pharmaceutical Company; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; and Sanofi. COPDGene was supported by award no. R01 HL089897 and award no. R01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. The COPDGene® project is also supported by the COPD Foundation through contributions made to an industry advisory board comprising AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion.
Publisher Copyright:
© 2017, Society of General Internal Medicine.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Background: Electronic cigarettes (e-cigarettes) are battery-operated nicotine-delivery devices used by some smokers as a cessation tool as well as by never smokers. Objective: To determine the usage of e-cigarettes in older adults at risk for or with chronic obstructive pulmonary disease (COPD). Design: Prospective cohorts. Participants: COPDGene (N = 3536) and SPIROMICS (N = 1060) subjects who were current or former smokers aged 45–80. Main Measures: Participants were surveyed to determine whether e-cigarette use was associated with longitudinal changes in COPD progression or smoking habits. Key Results: From 2010 to 2016, participants who had ever used e-cigarettes steadily increased to 12–16%, but from 2014 to 2016 current use was stable at ~5%. E-cigarette use in African-Americans (AA) and whites was similar; however, AA were 1.8–2.9 times as likely to use menthol-flavored e-cigarettes. Current e-cigarette and conventional cigarette users had higher nicotine dependence and consumed more nicotine than those who smoked only conventional cigarettes. E-cigarette users had a heavier conventional cigarette smoking history and worse respiratory health, were less likely to reduce or quit conventional cigarette smoking, had higher nicotine dependence, and were more likely to report chronic bronchitis and exacerbations. Ever e-cigarette users had more rapid decline in lung function, but this trend did not persist after adjustment for persistent conventional cigarette smoking. Conclusions: E-cigarette use, which is common in adults with or at risk for COPD, was associated with worse pulmonary-related health outcomes, but not with cessation of smoking conventional cigarettes. Although this was an observational study, we find no evidence supporting the use of e-cigarettes as a harm reduction strategy among current smokers with or at risk for COPD.
AB - Background: Electronic cigarettes (e-cigarettes) are battery-operated nicotine-delivery devices used by some smokers as a cessation tool as well as by never smokers. Objective: To determine the usage of e-cigarettes in older adults at risk for or with chronic obstructive pulmonary disease (COPD). Design: Prospective cohorts. Participants: COPDGene (N = 3536) and SPIROMICS (N = 1060) subjects who were current or former smokers aged 45–80. Main Measures: Participants were surveyed to determine whether e-cigarette use was associated with longitudinal changes in COPD progression or smoking habits. Key Results: From 2010 to 2016, participants who had ever used e-cigarettes steadily increased to 12–16%, but from 2014 to 2016 current use was stable at ~5%. E-cigarette use in African-Americans (AA) and whites was similar; however, AA were 1.8–2.9 times as likely to use menthol-flavored e-cigarettes. Current e-cigarette and conventional cigarette users had higher nicotine dependence and consumed more nicotine than those who smoked only conventional cigarettes. E-cigarette users had a heavier conventional cigarette smoking history and worse respiratory health, were less likely to reduce or quit conventional cigarette smoking, had higher nicotine dependence, and were more likely to report chronic bronchitis and exacerbations. Ever e-cigarette users had more rapid decline in lung function, but this trend did not persist after adjustment for persistent conventional cigarette smoking. Conclusions: E-cigarette use, which is common in adults with or at risk for COPD, was associated with worse pulmonary-related health outcomes, but not with cessation of smoking conventional cigarettes. Although this was an observational study, we find no evidence supporting the use of e-cigarettes as a harm reduction strategy among current smokers with or at risk for COPD.
KW - COPD
KW - electronic cigarette
KW - lung function
KW - tobacco
UR - http://www.scopus.com/inward/record.url?scp=85028958769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028958769&partnerID=8YFLogxK
U2 - 10.1007/s11606-017-4150-7
DO - 10.1007/s11606-017-4150-7
M3 - Article
C2 - 28884423
AN - SCOPUS:85028958769
VL - 32
SP - 1315
EP - 1322
JO - Journal of General Internal Medicine
JF - Journal of General Internal Medicine
SN - 0884-8734
IS - 12
ER -